Anticoagulant and antithrombotic activity of seaweed sulfated polysaccharides: 615.32:616.151:616-005

Abstract

Modern literature data on the anticoagulant, antithrombotic and fibrinolytic activity of sulfated polysaccharides of seaweed (PS) are presented, depending on their structural features (content and position of sulfate groups on the main chain of PS, molecular weight, monosaccharide composition and type of glycosidic bonds, the degree of PS chain branching, etc.). The mechanisms of PS action on hemostasis are discussed in a comparative to heparin. The questions of oral bioavailability of PS, important for their clinical use as oral anticoagulants and antithrombotic agents, are considered. The combination of the anticoagulant, thrombolytic, fibrinolytic properties together with low toxicity and relative cheapness of production open up prospects for the clinical use of PS as alternative sources of new anticoagulant and antithrombotic compounds.

REFERENCES

1. Wells M.L., Potin P., Craigie J.S. et al. Algae as nutritional and functional food sources: Revisiting our understanding. J Appl Phycol. 2017;29(2):949–82. DOI: 10.1007/s10811–016–0974–5.
2. Springer G.F., Wurzel H.A., McNeal G.M.J. Isolation of anticoagulant fractions from crude fucoidan. Proc Soc Exp Biol Med. 1957;94(2):404–9. DOI: 10.3181/00379727–94–22960.
3. Silva T.M., Alves L.G., de Queiroz K.C. et al. Partial characterization and anticoagulant activity of a heterofucan from the brown seaweed Padina gymnospora. Braz J Med Biol Res. 2005;38(4):523–33. DOI: 10.1590/s0100–879x2005000400005.
4. Athukorala Y., Jung W.K., Vasanthan T., Jeon Y.J. An anticoagulative polysaccharide from an enzymatic hydrolysate of Ecklonia cava. Carbohydr Polym. 2006;66:184–91. DOI: 10.1016/j.carbpol.2006.03.002.
5. Mestechkina N.M., Shcherbukhin V.D. Sulfated polysaccharides and their anticoagulant activity: a review. [Sul’faty polisaharidov i ih antikoagulyantnaya aktivnost’ (obzor)]. Prikladnaya biohimiya i mikrobiologiya. 2010;46(3):291–8. (In Russ.). DOI: 10.1134/ S000368381003004X.
6. Wang J., Zhang Q.B., Zhang Z.S. et al. Potential antioxidant and anticoagulant capacity of low molecular weight fucoidan fractions extracted from Laminaria japonica. Int J Biol Macromol. 2010;46(1):6–12. DOI: 10.1016/j.ijbiomac.2009.10.015.
7. Minh Thu Q.T., Vu Luong D., Nguyen Thi Nu N. et al. Effect of sulfation on the structure and anticoagulant activity of ulvan extracted from green seaweed Ulva reticulata. Vietnam J Sci Technol. 2018;54(2C):373–9.
8. Liu X., Du P., Liu X. et al. Anticoagulant properties of a green algal rhamnan-type sulfated polysaccharide and its low-molecularweight fragments prepared by mild acid degradation. Mar Drugs. 2018;16(11):445. DOI: 10.3390/md16110445.
9. Adrien A., Bonnet A., Dufour D. et al. Anticoagulant activity of sulfated ulvan isolated from the Green Macroalga Ulva rigida. Mar Drugs. 2019;17(5):291. DOI: 10.3390/md17050291.
10. Li H., Mao W., Zhang X. et al. Structural characterization of an anticoagulant-active sulfated polysaccharide isolated from green alga Monostroma latissimum. Carbohydr Polym. 2011;85(2):394– 400. DOI: 10.1016/j.carbpol.2011.02.042.
11. Synytsya A., Choi D.J., Pohl R. et al. Structural features and anti-coagulant activity of the sulphated polysaccharide SPSCF from a green alga Capsosiphon fulvescens. Mar Biotechnol. 2015;17(6):718–35. DOI: 10.1007/s10126–015–9643-y.
12. Yoon S.J., Pyun Y.R., Hwang J.K., Mourão P.A.S. A sulfated fucan from the brown alga Laminaria cichorioides has mainly heparin cofactor II-dependent anticoagulant activity. Carbohydr Res. 2007;342(15):2326–30. DOI: 10.1016/j.carres.2007.06.019.
13. Yang C., Chung D., Shina I.S. et al. Effects of molecular weight and hydrolysis conditions on anticancer activity of fucoidans from sporophyll of Undaria pinnatifida. Int J Biol Macromol. 2008;43(5):433– 7. DOI: 10.1016/j.ijbiomac.2008.08.006.
14. PominV.H.,PereiraM.S.,ValenteA.P.etal.Selectivecleavageand anticoagulant activity of a sulfated fucan: stereospecific removal of a 2-sulfate ester from the polysaccharide by mild acid hydrolysis, preparation of oligosaccharides, and heparin cofactor II-dependent anticoagulant activity. Glycobiology. 2005;15(4):369–81. DOI: 10.1093/glycob/cwi021.
15. Boisson-Vidal C., Chaubet F., Chevolot L. et al. Relationship between antithrombotic activities of fucans and their structure. Drug Devel Res. 2000;51(4):216–24. DOI: 10.1002/ddr.2.
16. Lahrsen E., Schoenfeld A.K., Alban S. Size-dependent pharmacological activities of differently degraded fucoidan fractions from Fucus vesiculosus. Carbohydr Polym. 2018;189:162–8. DOI:10.1016/j. carbpol.2018.02.035.
17. Choi Y., Min S.K., Usoltseva R. et al. Thrombolytic fucoidans inhibit the tPA-PAI1 complex, indicating activation of plasma tissue-type plasminogen activator is a mechanism of fucoidan-mediated thrombolysis in a mouse thrombosis model. Thromb Res. 2018;161:22–5. DOI: 10.1016/j.thromres.2017.11.015.
18. MinS.K.,HanS.M.,JangJ.S.,KimJ.K.Stimulatoryeffectofanalgal fucoidan on the release of vascular endothelial tissue-type plasminogen activator as a mechanism of fucoidan-mediated thrombolysis. Blood Coagul Fibrinolysis. 2016;27(5):594–6. DOI: 10.1097/ MBC.0000000000000522.

19. Cao S., He X., Qin L. et al. Anticoagulant and antithrombotic properties in vitro and in vivo of a novel sulfated polysaccharide from marine green alga Monostroma nitidum. Mar Drugs. 2019;17(4). pii: E247. DOI: 10.3390/md17040247.

20. Juenet M., Aid-Launais R., Li B. et al. Thrombolytic therapy based on fucoidan-functionalized polymer nanoparticles targeting Pselectin. Biomaterials. 2018;156:204–16. DOI: 10.1016/j.biomaterials.2017.11.047.

21. Qiu X., Amarasekara A.S., Doctor V.M. Effect of oversulfation on the chemical and biological properties of fucoidan. Carbohydr Polym. 2006;63(2):224–8. DOI: 10.1016/j.carbpol.2005.08.064.

22. Hall G., Lang D., Qiu X., Doctor V. Effect of native fucoidan, sulfated fucoidan, heparin and 6-aminohexanoic acid on the activation of glutamic-plasminogen by urokinase: role of NaCl. Blood Coagul Fibrinolysis. 2006;17(4):277–81. DOI: 10.1097/01. mbc.0000224847.12131.89.

23. Hirsh J., Warkentin T.E., Shaughnessy S.G. et al. Heparin and lowmolecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest. 2001;119(1 Suppl):64S-94S. DOI: 10.1378/chest.119.1_suppl.64s.

24. Hoppensteadt D., Walenga J.M., Fareed J., Bick R.L. Heparin, lowmolecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation. Hematol Oncol Clin North Am. 2003;17(1):313–41. DOI: 10.1016/s0889–8588(02)00091–6.

25. Kuznetsova T.A., Besednova N.N., Barkagan Z.S. et al. Anticoagulant activity of fucoidan from brown alga Fucus evanescens of the Okhotsk Sea. [Antikoagulyantnaya aktivnost’ fukoidana iz buroj vodorosli Ohotskogo morya Fucus evanescens]. Tromboz, gemostaz i reologiya. 2003;(4):36–9. (In Russ.).

26. Melo F.R., Pereira M.S., Foguel D., Mourão P.A.S. Antithrombinmediated anticoagulant activity of sulfated polysaccharides: different mechanisms for heparin and sulfated galactans. J Biol Chem. 2004;279(20):20824–35. DOI: 10.1074/jbc.M308688200.

27. Lapikova E.S., Drozd N.N., Tolstenkov A.S. et al. Inhibition of thrombin and factor Xa by Fucus evanescens fucoidan and its modified analogs. Bull Exp Biol Med. 2008;146(3):328–33. DOI: 10.1007/s10517–008–0267–3

28. Jung W.K., Athukorala Y., Lee Y.J. et al. Sulfated polysaccharide purified from Ecklonia cava accelerates antithrombin III-mediated plasma proteinase inhibition. J Appl Phycol. 2007;19(5):425– 30. DOI: 10.1007/s10811–006–9149–0.
29. Becker C.F., Guimarães J.A., Mourão P.A.S., Verli H. Conformation of sulfated galactan and sulfated fucan in aqueous solutions: Implications to their anticoagulant activities. J Mol Graph Model. 2007;26(1):391–9. DOI: DOI: 10.1016/j.jmgm.2007.01.008.
30. Wang Y., Xing M., Cao Q. et al. Biological activities of fucoidan and the factors mediating its therapeutic effects: a review of recent studies. Mar Drugs. 2019;17(3). pii: E183. DOI: 10.3390/md17030183.
31. Li N., Zhang Q., Song J. Toxicological evaluation of fucoidan extracted from Laminaria japonica in Wistar rats. Food Chem Toxicol. 2005;43(3):421–6. DOI: 10.1016/j.fct.2004.12.001.
32. Prasad S., Lillicrap D., Labelle A. et al. Efficacy and safety of a newclass hemostatic drug candidate, AV513, in dogs with hemophilia A. Blood. 2008;111(2):672–9. DOI: 10.1182/blood-2007–07–098913.
33. Gideon T.P., Rengasamy R. Toxicological evaluation of fucoidan from Cladosiphon 33. okamuranus. J Med Food. 2008;11(4):638– 42. DOI: 10.1089/jmf.2007.0127.
34. Zhao X., Guo F., Hu J. et al. Antithrombotic activity of oral administered low molecular weight fucoidan from Laminaria japonica. Thromb Res. 2016;144:46–52. DOI: 10.1016/j.thromres.2016.03.008.
35. Obluchinskaya E.D., Karlina M.V., Pozharitskaya O.N. et al. Pharmaceutical composition based on fucoidan for oral administration and a method for its preparation. [Farmacevticheskaya kompoziciya na osnove fukoidana dlya peroral’nogo primeneniya i sposob eyo polucheniya]. Patent RF No 2657615 ot 14.06.2018. Byul. No 17. 13 s. (In Russ.). Available at: https://rusneb.ru/catalog/000224_000128_0002657615_20180614_C1_RU. [Accessed: 20.11.2019].
36. Kryzhanovskiy S.P., Kuznetsova T.A., Bogdanovich L.N., Golovachova V.D. Effect of polysaccharides from brown algae on hemostasis in experiment and clinic. [Vliyanie polisaharidov iz buryh vodoroslej na pokazateli sistemy gemostaza v eksperimental’nyh i klinicheskih usloviyah]. Tromboz, gemostaz i reologiya. 2014;(3):25– 30. (In Russ.).